Arrhythmias & electrophysiology
A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial
Study context
- Population
- Patients with prior MI (ischemic cardiomyopathy) and ventricular tachycardia (VT) despite ICDs
- Planned comparison
- Catheter ablation vs antiarrhythmic drug therapy as first-line therapy
- Primary endpoint
- Composite of:
- Mortality at any time
- Appropriate ICD shock
- VT storm
- Treated sustained VT below ICD detection (each after 14 days)
- Follow-up
- Until 2 years after randomization
Methodological detailsdesign and rationale, stratified randomisation by drug-eligibility group, intention-to-treat analysis, Drug therapy, ablation procedures and ICD programming standardized
- Design and rationale
- Stratified randomisation by drug-eligibility group
- Intention-to-treat analysis
- Drug therapy, ablation procedures and ICD programming standardized
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial. Am Heart J. Published 21 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →